Life Sciences Growth Equity

Structure

Growth equity sits between venture capital and buyout. A venture investor funds scientific or product risk before revenue. A buyout investor typically acquires control of a mature business, often with borrowed money. A life sciences growth equity investor buys a minority stake in a company that has crossed the line from development to sales, and supplies primary capital for the next stage of growth. The broader category is covered in Growth Equity; this entry concerns its application to life sciences.

The profile of a typical target differs from an early-stage company in four ways.

• Revenue exists: the product is cleared or approved and customers pay, which allows valuation against revenue or earnings and not against milestones alone.
• Reimbursement is established or visible: coverage decisions, billing codes and payer contracts are largely known, so revenue quality can be tested.
• Capital funds scale: sales force, manufacturing, new indications, geographic expansion or acquisitions.
• Governance is negotiated: a minority investor cannot decide alone, so protective provisions, board seats and information rights carry weight, along with a defined path to liquidity.

Segments include commercial-stage diagnostics, medical devices, tools and services to drug developers, and healthcare technology and services. The regulatory features of laboratory testing are described in Laboratory-Developed Tests and CLIA.

Worked Example

Consider a hypothetical commercial-stage diagnostics company with $30 million in annual revenue. An investor values it at 4.0 times revenue, or $120 million before new money, and buys $30 million of newly issued shares. The company's value after the investment is $150 million, so the investor owns $30 million ÷ $150 million = 20 percent. The company uses the proceeds to expand its sales team and add a second laboratory.

Revenue of $30 million growing 25 percent a year reaches $30 × 1.25⁵ = $91.6 million. At the same 4.0-times multiple, the company is worth $366.2 million, and a 20 percent stake is worth $73.2 million, for 2.44 times the amount invested. Over five years that equals an annual rate of about 19.5 percent. Each assumption can fail. If growth slows to 15 percent, year-five revenue is $60.3 million, exit value is $241.4 million and the stake is worth $48.3 million, or 1.61 times. If the exit multiple compresses to 3.0 times at 25 percent growth, the stake is worth $54.9 million, or 1.83 times. Further dilution from option grants or later financings would reduce the result again. The calculation of the multiple is explained in Multiple on Invested Capital.

Life Sciences Growth Equity: What Investors Underwrite

Investors in this segment test a short list of questions before committing.

1. Quality of revenue: how much comes from recurring use of the product, how concentrated the customers are, and how much depends on a single payer or contract.
2. Reimbursement durability: whether coverage and payment rates are stable, and what happens if a payer changes policy.
3. Unit economics: gross margin, cost to acquire a customer and the payback period on a sales hire.
4. Regulatory position: clearances, approvals, quality systems and inspection history.
5. Management and operations: whether the team can scale a laboratory, factory or care network without losing quality. An experienced operating partner, described in Operating Partner, often helps with this step.
6. Path to liquidity: the likely buyers or public-market route, and the rights that make an exit possible for a minority holder.

What It Means for a Limited Partner

For a limited partner, life sciences growth equity offers a different risk profile from early-stage venture. Capital goes to companies with revenue, so outcomes depend less on binary scientific events and more on execution and reimbursement. Losses still occur when a company with revenue misses its plan. Allocators should ask how the manager sources companies outside broad auctions, how it values revenue-based deals and how it protects a minority position through governance rights. They should examine the manager's record of value creation by company, separating growth in the business from changes in the valuation multiple, since multiple expansion cannot be counted on. Finally, check that sector knowledge is real: a manager that has diligenced reimbursement and regulatory questions repeatedly will price risk better than a generalist. The earlier stage of the same sector is covered in life sciences venture capital fund.

In Life Sciences and Healthcare

The segment covers commercial-stage companies in biopharma services and tools, diagnostics and precision medicine, devices and robotics, digital health and care delivery, and longevity and neuroscience. Many are also technology companies, and artificial intelligence increasingly affects their cost structure, product quality and speed, as an accelerant of the business and not as a separate sector. A healthcare company that is also a technology business, and applies data to its product, can be attractive precisely because it combines recurring revenue with a defensible clinical position. The thesis behind this approach appears in healthcare growth equity.

Frequently Asked Questions

What is life sciences growth equity?

It is minority capital invested in commercial-stage healthcare and life sciences companies that already sell products or services and need funding to scale. The investor typically buys newly issued shares, takes a board seat and protective rights, and expects a return through a later sale or public offering.

How is growth equity different from venture capital in life sciences?

Venture capital funds companies before revenue, where scientific and clinical results decide outcomes. Growth equity funds companies with revenue, where execution, reimbursement and unit economics matter more. Valuation relies on revenue or earnings multiples, and the path to an exit is usually shorter.

How do investors value a commercial-stage life sciences company?

Investors usually apply a multiple of revenue or earnings drawn from comparable companies, adjusted for growth, margin, reimbursement and regulatory risk. In the example above, 4.0 times revenue produced a $120 million value before investment. They then test how the result changes if growth slows or the multiple falls.

Related Reference

This entry applies the broader thesis of healthcare growth equity. Related entries: Growth Equity, Multiple on Invested Capital and The Mid-Market in Private Equity.